ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Louisville, KY, USA:

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Louisville, Kentucky, United States and 31 other locations

of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma...

Enrolling
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Drug: ATA3219

Phase 1

Atara Biotherapeutics

Louisville, Kentucky, United States and 2 other locations

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...

Enrolling
EBV Associated Lymphoma
EBV Related Non-Hodgkin's Lymphoma
Drug: Nanatinostat in combination with valganciclovir

Phase 2

Viracta Therapeutics

Louisville, Kentucky, United States and 94 other locations

of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comp...

Active, not recruiting
Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Large B Cell Lymphoma
Genetic: ALLO-501
Drug: Fludarabine

Phase 1

Allogene Therapeutics

Louisville, Kentucky, United States and 6 other locations

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemoth...

Enrolling
Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Drug: Gemcitabine
Drug: Rituximab

Phase 3

ADC Therapeutics

Louisville, Kentucky, United States and 143 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Louisville, Kentucky, United States and 186 other locations

trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary object...

Enrolling
Non Hodgkin Lymphoma
Drug: Interleukin-2
Drug: Rituximab

Phase 1, Phase 2

Artiva Biotherapeutics

Louisville, Kentucky, United States and 20 other locations

of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabin...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Louisville, Kentucky, United States and 33 other locations

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma...

Enrolling
Diffuse Large B-cell Lymphoma
Drug: Selinexor

Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Louisville, Kentucky, United States and 175 other locations

and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Large B Cell Lymphoma
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 2

Allogene Therapeutics

Louisville, Kentucky, United States and 1 other location

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems